Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p-Reference-Cited by-同舟云学术

Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p

Published:2018-08-10 Issue:15 Volume:2 Page:1946-1956
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Barnes James I.¹²^ORCID,Divi Vasu³,Begaye Adrian⁴,Wong Russell⁵,Coutre Steven⁶,Owens Douglas K.¹²,Goldhaber-Fiebert Jeremy D.²

Affiliation:

1. Veterans Affairs Palo Alto Health Care System, Palo Alto, CA;

2. Center for Primary Care and Outcomes Research/Center for Health Policy, Department of Medicine, Stanford University School of Medicine,

3. Department of Otolaryngology–Head and Neck Surgery,

4. Stanford University School of Medicine,

5. Department of Management Science and Engineering, and

6. Division of Hematology, Stanford University School of Medicine, Stanford University, Stanford, CA

Abstract

Key Points At current prices, ibrutinib is not a cost-effective initial CLL therapy in older patients without 17p deletion. The cost of ibrutinib would need to be <$6800 per month to be cost-effective.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/2/15/1946/881401/advances015461.pdf

Reference51 articles.

1. Cancer statistics, 2015;Siegel;CA Cancer J Clin,2015

2. National Cancer Institute, Surveillance, Epidemiology, and End Results. Cancer Stat Facts: Leukemia—Chronic Lymphocytic Leukemia (CLL). https://seer.cancer.gov/statfacts/html/clyl.html. Accessed 13 February 2018.

3. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia;Byrd;N Engl J Med,2013

4. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia;Byrd;N Engl J Med,2014

5. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia;Burger;N Engl J Med,2015

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assay-guided treatment sequencing in chronic lymphocytic leukemia (CLL): a cost-effectiveness analysis;Scientific Reports;2024-07-27

2. Real-world comparison of health care costs of venetoclax-obinutuzumab vs Bruton’s tyrosine kinase inhibitor use among US Medicare beneficiaries with chronic lymphocytic leukemia in the frontline setting;Journal of Managed Care & Specialty Pharmacy;2024-07-24

3. Considering Returns on Federal Investment in the Negotiated “Maximum Fair Price” of Drugs Under the Inflation Reduction Act: an Analysis;2024-02-28

4. Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia;PharmacoEconomics;2024-01-06

5. Ibrutinib versus bendamustine plus rituximab for first-line treatment of 65 or older patients with untreated chronic lymphocytic leukemia without del(17p)/TP53 mutation in China: a lifetime economic research study;BMC Health Services Research;2023-12-05